靶向抗肿瘤单克隆抗体药物应用的现状和展望-中国肿瘤生物治疗杂志.PDFVIP

中国肿瘤生物治疗杂志 Chin J Cancer Biother, Sep. 2017, Vol. 24, No. 9 ·929 · DOI：：10.3872/j.issn.1007-385x.2017.09.001 ∙专家论坛∙ 靶向抗肿瘤单克隆抗体药物应用的现状和展望 张敏，李佳，俞德超（信达生物制药（苏州）有限公司，江苏苏州 215123 ） [摘 要] 随着对抑制肿瘤信号通路、抑制肿瘤生长相关血管生成通路以及活化免疫系统发挥抗肿瘤作用等靶向抗肿瘤方法研 究的不断进展，抗肿瘤抗体药物已经成为肿瘤领域不可或缺的治疗手段。临床批准的靶向抗肿瘤抗体药物主要包括分子靶向单 克隆抗体（单抗）药物、抗体偶联药物、双特异性抗体药物以及靶向免疫检验点药物。近年来，肿瘤免疫治疗越发火热，上述具有 免疫调节作用的抗体药物，或能增加肿瘤抗原性，或能促进肿瘤T 细胞浸润，已经取得了巨大的临床收益；单抗药物的联用是未 来的一大发展重点，无论是与肿瘤免疫疗法联用、与分子靶向抗体药物联用、与放化疗和小分子抑制剂药物甚至手术的联用，都 将进一步提高抗体类药物在抗肿瘤治疗中的实用价值。 [关键词] 单克隆抗体；肿瘤免疫治疗；免疫检验点；药物联用；双特异性抗体 [中图分类号] R730.51 ；R797.1 [文献标识码] A [文章编号] 1007-385X （2017 ）09-0929-09 The development trend of therapeutic monoclonal antibodies for cancer therapy ZHANG Min, LI Jia, YU Dechao （Innovent Biologics, Suzhou 215123, Jiangsu, China） [Abstract] Many advances in the treatment of cancer have been driven by the development of targeted therapies that inhibit oncogenic signaling pathways and tumor-associated angiogenesis, as well as by the therapies that acti- vate immune system to unleash antitumor immunity. Many clinically approved therapies, including monoclonal anti- bodies ，antibody-drug conjugates ，bispecific antibodies and immune checkpoints, have become important strategies for cancer treatment. Recently, tumor immunotherapy is becoming more and more popular, and antibody medicines acquiring above mentioned immune-modulating effects, such as increasing tumor antigenicity or promoting intratu- moral T cell infiltration, had achieved great clinical benefits; monoclonal antibody medicine in combination with tu- mor immunotherapy, molecular targeted antibody medicine, chemotherapy or small molecular inhibitors and even surgery, will further enlarge the application value of antibody medicines in tumor therapies. [Key words] monoclonal antibody ；tumor immunotherapy ；immune checkpoint ；combination ；bispecific antibody [Chin J Cancer Biot